Antiarrhythmic Effect of Sacubitril-Valsartan: Cause or Consequence of Clinical Improvement?
Sacubitril/Valsartan (LCZ696) reduced sudden cardiac death in the PARADIGM-HF trial. However, the mechanism by which LCZ696 reduces ventricular arrhythmias remains unclear. The aim of this study was to compare electrocardiographic (ECG) parameters and mechanical dispersion index, assessed by left ve...
Main Authors: | António Valentim Gonçalves, Tiago Pereira-da-Silva, Ana Galrinho, Pedro Rio, Luísa Moura Branco, Rui Soares, Joana Feliciano, Rita Ilhão Moreira, Rui Cruz Ferreira |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-06-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/8/6/869 |
Similar Items
-
Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01) -
Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline‐induced takotsubo‐like syndrome
by: Anwar Ali, et al.
Published: (2021-10-01) -
Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty
by: Francesco Cacciatore, et al.
Published: (2020-04-01) -
Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
by: Ying‐Hsiang Lee, et al.
Published: (2021-04-01) -
The effects of sacubitril/valsartan and ramipril on the male fertility in hypertensive rats
by: Duygun Altıntaş Aykan, et al.
Published: (2020-10-01)